229 related articles for article (PubMed ID: 29760048)
1. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.
Untch BR; Dos Anjos V; Garcia-Rendueles MER; Knauf JA; Krishnamoorthy GP; Saqcena M; Bhanot UK; Socci ND; Ho AL; Ghossein R; Fagin JA
Cancer Res; 2018 Aug; 78(16):4642-4657. PubMed ID: 29760048
[TBL] [Abstract][Full Text] [Related]
2. Tipifarnib as a Precision Therapy for
Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
4. Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma.
Jagadeeshan S; Suryamohan K; Shin N; Mathukkada S; Boyko A; Melikhova D; Tsareva A; Yunusova L; Pravdivtseva E; Stupichev D; Shaposhnikov K; Peterson A; Bednyagin L; Shugaev-Mendosa E; Kessler L; Burrows F; Ho AL; Agrawal N; Pearson AT; Izumchenko E; Cole G; Elkabets M; Rosenberg AJ
Oral Oncol; 2024 Feb; 149():106688. PubMed ID: 38219706
[TBL] [Abstract][Full Text] [Related]
5. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
[TBL] [Abstract][Full Text] [Related]
6. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract][Full Text] [Related]
7. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
Lee HW; Sa JK; Gualberto A; Scholz C; Sung HH; Jeong BC; Choi HY; Kwon GY; Park SH
Clin Cancer Res; 2020 Oct; 26(19):5113-5119. PubMed ID: 32636318
[TBL] [Abstract][Full Text] [Related]
8. GNAS(R201H) and Kras(G12D) cooperate to promote murine pancreatic tumorigenesis recapitulating human intraductal papillary mucinous neoplasm.
Taki K; Ohmuraya M; Tanji E; Komatsu H; Hashimoto D; Semba K; Araki K; Kawaguchi Y; Baba H; Furukawa T
Oncogene; 2016 May; 35(18):2407-12. PubMed ID: 26257060
[TBL] [Abstract][Full Text] [Related]
9. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
[TBL] [Abstract][Full Text] [Related]
10. Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors.
Nigam A; Krishnamoorthy G; Chatila W; Berman K; Saqcena M; Walch H; Ho A; Schultz N; Fagin J; Untch B
Res Sq; 2023 Jul; ():. PubMed ID: 37503077
[TBL] [Abstract][Full Text] [Related]
11. KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.
Leiser D; Medová M; Mikami K; Nisa L; Stroka D; Blaukat A; Bladt F; Aebersold DM; Zimmer Y
Mol Oncol; 2015 Aug; 9(7):1434-46. PubMed ID: 25933688
[TBL] [Abstract][Full Text] [Related]
12. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
[TBL] [Abstract][Full Text] [Related]
13. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
14. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ; Guenette JP; Chau NG; Sayehli CM; Wilhelm C; Metcalf R; Wong DJ; Brose M; Razaq M; Pérez-Ruiz E; Cohen EEW; Aggarwal R; Scholz C; Gualberto A; Ho AL
Cancer; 2020 Sep; 126(17):3972-3981. PubMed ID: 32557577
[TBL] [Abstract][Full Text] [Related]
15. Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity.
Smith AE; Chan S; Wang Z; McCloskey A; Reilly Q; Wang JZ; Patel HV; Koshizuka K; Soifer HS; Kessler L; Dayoub A; Villaflor V; Adkins DR; Bruce JY; Ho AL; Perez CA; Hanna GJ; Gascó Hernández A; Saunders A; Dale S; Gutkind JS; Burrows F; Malik S
Cancer Res; 2023 Oct; 83(19):3252-3263. PubMed ID: 37339176
[TBL] [Abstract][Full Text] [Related]
16. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
[TBL] [Abstract][Full Text] [Related]
17. Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient.
Lee HW; Chung W; Lee HO; Jeong DE; Jo A; Lim JE; Hong JH; Nam DH; Jeong BC; Park SH; Joo KM; Park WY
Genome Med; 2020 May; 12(1):47. PubMed ID: 32460812
[TBL] [Abstract][Full Text] [Related]
18. Targeting HRAS in Head and Neck Cancer: Lessons From the Past and Future Promise.
Desilets A; Ho AL
Cancer J; 2022 Sep-Oct 01; 28(5):363-368. PubMed ID: 36165724
[TBL] [Abstract][Full Text] [Related]
19. Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma.
Hang JF; Pan CC
Pathology; 2017 Apr; 49(3):316-317. PubMed ID: 28285720
[No Abstract] [Full Text] [Related]
20. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
